Skip to main content

Table 1 Selected patients’ characteristics

From: Promoter hypermethylation and silencing of tissue factor pathway inhibitor-2 in oral squamous cell carcinoma

(a) TFPI-2 methylation level by qMSP
  n (%) Mean SD Median IQR
Gender       
 Male 110 (100) 13.64 13.05 8.94 21.06
Pathological Stage       
 Normal 24 (21.8) 4.45 7.51 1.79 1.62
 I 20 (18.2) 16.23 12.97 13.87 16.71
 II 12 (10.9) 12.96 12.46 6.96 23.95
 III 25 (22.7) 17.19 13.62 16.86 23.15
 IV 29 (26.4) 16.67 13.60 16.64 19.61
Cancer Site       
 Buccal 36 (41.9) 17.05 12.46 15.95 18.90
 Tongue 50 (58.1) 15.59 13.71 11.66 22.63
(b) TFPI-2 methylation level by pyrosequencing
  n (%) Mean SD Median IQR
Gender       
 Male 60 (100) 18.80 14.99 15.58 23.79
Pathological Stage       
 Normal 11 (18.3) 4.43 1.91 3.82 2.94
 I 15 (25.0) 20.35 12.19 18.26 23.14
 II 12 (20.0) 16.21 9.48 12.17 12.97
 III 14 (23.3) 21.63 16.08 21.03 28.34
 IV 8 (13.3) 34.63 18.06 33.10 23.50
Cancer Site       
 Buccal 19 (38.8) 29.70 14.41 28.12 16.07
 Tongue 30 (61.2) 17.18 12.96 13.86 20.82
  1. SD: standard deviation; IQR: interquartile range.